X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Patients pay the price when hospitals mark up cancer medicines

By Joe Vandigo  |    April 5, 2018
Two studies released last month reveal how hospitals across the country mark up the price of medicines and deliver a growing share of provider-administered medicines, resulting in higher costs...   Read More

340B Spotlight: How much money are hospitals pocketing under 340B and what are they doing with those profits?

By Nicole Longo  |    March 28, 2018
The once little-known 340B drug discount program, which was designed to help low-income, uninsured or otherwise vulnerable patients access prescription medicines at safety-net facilities, is now a...   Read More

340B Spotlight: Hospital system adds voice to comments about flawed 340B program

By Nicole Longo  |    February 2, 2018
Each week, more and more groups are calling attention to the 340B program and its myriad problems. Here’s a quick recap of some of the latest voices out there.   Read More

340B Spotlight: New pieces of legislation continue momentum to fix 340B program

By Nicole Longo  |    January 18, 2018
In case you missed it, two new pieces of legislation have been introduced to increase oversight of and fix the 340B program. Before the holidays, Representatives Larry Bucshon and Scott Peters...   Read More

340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform

By Nicole Longo  |    October 20, 2017
Evidence that the 340B program has strayed from its congressionally stated intent – and is now benefiting wealthy hospitals instead of patients – has been piling up, and members of Congress have...   Read More

How much are hospitals marking up the price of medicines? The answer may surprise you.

By Robert Zirkelbach  |    October 17, 2017
Hospitals mark up medicine prices, on average, nearly 500 percent, according to a new analysis from the Moran Company that was commissioned by the Pharmaceutical Research and Manufacturers of...   Read More

340B Spotlight: New analysis finds 340B program growth continues to accelerate despite false claims

By Nicole Longo  |    July 13, 2017
This week, Berkeley Research Group (BRG) released a new whitepaper pushing back on the highly misleading claim that 340B sales are only 2 percent of annual U.S. drug sales. Citing a number of...   Read More

340B Spotlight: ICYMI – AJC looks at how some Georgia hospitals are profiting off 340B

By Nicole Longo  |    June 20, 2017
In case you missed it, the Atlanta Journal-Constitution analyzed data on hospital participation in the 340B program in Georgia and found that some hospitals are raking in huge profits – with no...   Read More

340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients

By Rebecca Davison  |    April 27, 2017
As we’ve noted before, incentives to profit under the 340B program are leading to an uneven playing field for providers and may be shifting care to more expensive and less convenient settings in...   Read More

340B Spotlight: Audit findings show importance of increased oversight of 340B program

By Rebecca Davison  |    February 9, 2017
The 340B Drug Discount Program is an important component of the health care safety net, providing help to vulnerable or uninsured patients. However, with great power comes great responsibility,...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates